癫痫的耐药性
耐药性癫痫估计影响约三分之一的癫痫患者,其患病率随癫痫综合征、病因、发病年龄及是否伴有神经功能缺损等因素而异。两种恰当使用的抗癫痫发作药物未能控制发作后,应尽可能转诊至综合癫痫中心进行诊断再评估与针对性管理。有大量证据表明,延迟识别有效治疗可对最终结局产生不利影响,并增加认知障碍、其他共病及过早死亡的风险。
要点
- 耐药性癫痫估计影响约三分之一的癫痫患者,患病率随综合征、病因等因素不同。
- 两种恰当使用的抗癫痫发作药物未能控制发作后,应尽可能转诊至综合癫痫中心。
- 延迟识别有效治疗可对最终结局产生不利影响,并增加认知障碍、共病及过早死亡风险。
核心结论
- 耐药性癫痫估计影响约三分之一的癫痫患者,但耐药性癫痫并不等同于对任何药物治疗无反应。
- 随着既往失败治疗数目增加,新尝试药物达到无发作的概率降低。
- 两种恰当使用的抗癫痫发作药物未能控制发作后,应尽可能转诊至综合癫痫中心进行诊断再评估与针对性管理。
- 有大量证据表明,延迟识别有效治疗可对最终结局产生不利影响,并增加认知障碍、其他共病及过早死亡的风险。
主要发现
- 耐药性癫痫的患病率随癫痫综合征、癫痫病因、发病年龄及是否伴有相关神经功能缺损等因素而异。
- 耐药性癫痫并不等同于对任何药物治疗无反应,但新尝试药物达到无发作的概率随既往失败治疗数目增加而降低。
临床怎么用
- 两种恰当使用的抗癫痫发作药物未能控制发作后,应尽可能将患者转诊至综合癫痫中心进行诊断再评估与针对性管理。
- 诊断后应尽早考虑癫痫手术及其他治疗(包括针对癫痫病因的治疗)的可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug resistance is estimated to affect about a third of individuals with epilepsy, but its prevalence differs in relation to the epilepsy syndrome, the cause of epilepsy, and other factors such as age of seizure onset and presence of associated neurological deficits. Although drug-resistant epilepsy is not synonymous with unresponsiveness to any drug treatment, the probability of achieving seizure freedom on a newly tried medication decreases with increasing number of previously failed treatments. After two appropriately used antiseizure medications have failed to control seizures, individuals should be referred whenever possible to a comprehensive epilepsy centre for diagnostic re-evaluation and targeted management. The feasibility of epilepsy surgery and other treatments, including those targeting the cause of epilepsy, should be considered early after diagnosis. Substantial evidence indicates that a delay in identifying an effective treatment can adversely affect ultimate outcome and carry an increased risk of cognitive disability, other comorbidities, and premature mortality. Research on mechanisms of drug resistance and novel therapeutics is progressing rapidly, and potentially improved treatments, including those targeting disease modification, are on the horizon.
引用
- Perucca E, Perucca P, White HS, et al. Drug resistance in epilepsy. Lancet Neurol. 2023. PMID: 37352888. doi:10.1016/S1474-4422(23)00151-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。